Mumbai, Feb. 25 -- YESINTEK is a biosimilar to Stelara (ustekinumab) and is one of the first biosimilar versions of Stelara to be introduced to the U.S. market.

The biosimilar is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, increasing patient access to more cost-effective treatment options for use in the treatment of common chronic autoimmune diseases. YESINTEK will be available in all the same formulations currently provided by Stelara.

At launch, YESINTEK will be covered by commercial payors and will also feature an extensive patient assistance program that includes benefits verification, copay support, and other services. The copay program is structured to be competitive...